Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board

Climb Bio, Inc., a clinical-stage biotechnology company focused on developing therapeutics for immune-mediated diseases, has appointed Douglas E. Williams, Ph.D., as the new Chair of its Board of Directors. Dr. Williams brings a wealth of experience in immunology drug development and executive leadership, which will significantly contribute to Climb Bio's growth and pipeline development.

Dr. Williams has over 30 years of executive leadership experience in the biotechnology sector, having held leadership roles in research and development at various companies. His expertise in immunology drug development will be particularly valuable as Climb Bio pursues its mission to develop better treatments for the approximately 50 million patients in the U.S. and many more globally living with immune-mediated diseases.



Dr. Williams' extensive experience in guiding companies from development to commercialization, including overseeing multiple mergers, will be crucial in advancing Climb Bio's pipeline and expanding its reach. His track record of successfully leading both private and public companies, along with his experience in mergers and acquisitions, signals a strategic reinforcement of Climb Bio's commitment to immune-mediated diseases.

One of Climb Bio's key pipeline assets is budoprutug, an anti-CD19 monoclonal antibody designed for a broad range of B-cell mediated diseases. Dr. Williams' expertise in immunology drug development will be particularly valuable in optimizing the clinical development of budoprutug and exploring additional indications within Climb Bio's pipeline.



Climb Bio's focus on immune-mediated diseases and its mission to develop better treatments for patients are further strengthened by Dr. Williams' appointment. With his deep knowledge of immunology drug development and proven track record in leading successful drug development programs, Dr. Williams will be instrumental in advancing Climb Bio's pipeline and delivering innovative therapies to patients.

In conclusion, Dr. Williams' appointment as Chair of the Board at Climb Bio signals a strategic commitment to the company's mission and pipeline. His extensive experience in immunology drug development and executive leadership will be invaluable in guiding Climb Bio's growth and ensuring the success of its pipeline, particularly for budoprutug. As Climb Bio continues to advance its therapies for immune-mediated diseases, investors can be confident that the company is in capable hands with Dr. Williams at the helm.